One Man’s Garage Lab and ChatGPT Yield a New Schizophrenia Candidate
5 Articles
5 Articles
One Man’s Garage Lab and ChatGPT Yield a New Schizophrenia Candidate
Douglas Yao used ChatGPT to design PAC-3310, a selective M4 muscarinic agonist for schizophrenia, then synthesized it in his garage lab. Early cell and mouse data show promise and high selectivity over Cobenfy. The project highlights AI's growing role in accelerating neuroscience drug discovery while raising questions about regulation and safety.
A man claims that he manufactured a new treatment for schizophrenia in his own garage, with the help of ChatGPT. Images of garage equipment have become viral on social networks.
Researcher Douglas Yao stated that with the help of ChatGPT, he had developed an experimental PAC-3310 for potential treatment of schizophrenia and then himself synthesized it in a chemical laboratory equipped in the garage.
One researcher says ChatGPT designed PAC-3310, a selective M4 muscarinic receptor agonist that he would have synthesized in a laboratory built in his garage. The statement, presented next to a compound vial, exposes both the potential of AI in pharmaceutical discovery and the risks of confusing a computational design with a validated drug.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
